Clinical Trial Update: Efficacy and Safety of Amantadine Hydrochloride (HCl) ER Tablets to Treat Parkinson's Disease Patients With LID. [Phase 3]

View source ↗

Summary

Phase 3 trial of extended-release amantadine HCl for Parkinson's disease with levodopa-induced dyskinesias was terminated; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Levodopa-induced Dyskinesias
• Parkinson Disease

Drugs mentioned

• Amantadine HCl ER Tablets (amantadine hydrochloride extended-release)

Snippet

Sponsor: Adamas Pharmaceuticals, Inc. | Conditions: Parkinson's Disease, Levodopa Induced Dyskinesias (LID) | Phase 3 | Status: TERMINATED | Results posted: 2019-04-02